The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Open Access
- 1 January 2017
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 103, 27-37
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- MET As a Possible Target for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsInvestigational New Drugs, 2012
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3Clinical Cancer Research, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET InhibitorsCancer Research, 2011
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibitionExpert Opinion on Drug Discovery, 2008
- Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerCancer Science, 2008